セッション詳細
[WS(P)29]Cell therapy, vaccine, and new therapeutic modality
2024年12月5日(木) 15:00 〜 15:45
Poster 7
[WS29-01-O/P]Development of new adoptive T cell therapy that overcomes tumor heterogeneity with escape variant tumor clones.
○Kiyoshi Yasui1, Daisuke Ehara1,2, Mitsuhiro Yoneda1, Situo Deng1, Sachiko Okamoto3, Yasunori Amaishi3, Daisuke Muraoka4, Naohisa Ogo5, Akira Asai5, Hiroyuki Murota2, Hiroaki Ikeda1 (1.Nagasaki Univ. Grad. Sch. of Biomed. Sci., Dept. of Oncology., 2.Nagasaki Univ. Grad. Sch. of Biomed. Sci., Dept. of Dermatology., 3.Tech. Development Ctr, Takara Bio Inc., 4.Aichi Cancer Ctr. Res. Inst., Div. of Translational Oncoimmunology., 5.Ctr. for Drug Discovery, Grad. Div. Pharm., Univ. of Shizuoka.)
[WS29-02-P]Development of a split and universal Chimeric Antigen Receptor system targeting solid tumors
○Hiroyuki Kadota, Tsukasa Shigehiro, Yuki Narita, Shogo Tanimori, Jia Han, Tomokatsu Ikawa (Tokyo University of Science, Research Institute for Biomedical Sciences)
[WS29-03-O/P]The relationship between receptor shedding andTrogocytosis
○Atsutaka Minagawa, Shin Kaneko (Kyoto University)
[WS29-04-O/P]Efficient production of CAR-NK cells with a potent antitumor effect using leukocyte progenitor cells
○Jia Han, Tsukasa Shigehiro, Shogo Tanimori, Hiroyuki Kadota, Karin Noma, Tomokatsu Ikawa (Tokyo University of Science, Research Institute for Biomedical Science)
[WS29-05-P]Development of CAR macrophage therapy for the treatment of solid tumors
○Kyoko Fukuda1, Masahiro Kariya2, Lan Yi Li3, Kazunobu Ohnuki1, Masamichi Ide2, Tetsuya Nakatsura1, Yuichiro Hagiya2, Tianyi Liu4, Yasushi Uemura1 (1.National Cancer Center, 2.Innovative Technology Lab., AGC Inc., 3.Dept. Cancer Therapy Develop. Beijing Tianyifang Bio. Dev. Co., Ltd, 4.Inst. Oncol. Chinese PLA General Hosp., Beijing, China)
[WS29-06-O/P]Imaging of biphasic signalosomes constructed by checkpoint receptor 2B4 in conventional and CAR-T cells
○Ryohei Matsushima1,2, Ei Wakamatsu1, Hiroaki Machiyama1, Wataru Nishi2, Yosuke Yoshida1,3, Tetsushi Nishikawa1,4, Hiroko Toyota1, Masae Furuhata1, Hitoshi Nishijima1, Arata Takeuchi1, Makoto Suzuki2, Tadashi Yokosuka1 (1.Tokyo Medical University department of Immunology, 2.Kumamoto University department of Thoracic Surgery, 3.Tokyo Medical University Department of Nephrology, 4.Tokyo Medical University Department of Dermatology)
[WS29-07-P]Endogenous TCRs contribute CAR-T cells activation by clustering with self antigen-MHCs
○Hiroaki Machiyama1, Ei Wakamatsu1, Arata Takeuchi1, Hitoshi Nishijima1, Masae Furuhata1, Hiroko Toyota1, Mamonkin Maksim2, Tadashi Yokosuka1 (1.Tokyo Medical University, 2.Baylor College of Medicine)
[WS29-08-O/P]Breast cancer specific antigen recognition by TIL-derived MR1-restricted TCRs
○Abdul Hayee1, Eiji Kobayashi1, Hiroshi Hamana2, Chihiro Motozono3, Satoshi Yamaguchi1, Ha Thi Viet My1, Tatsuhiko Ozawa1, Hiroyuki Kishi1 (1.Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan, 2.Shinobi Therapeutics Co., Ltd., Kyoto, Japan, 3.Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan)
[WS29-09-P]Identification of tumor-reactive T-cell clones proliferating in tumor-draining lymph nodes.
○Mikiya Tsunoda1, Munetomo Takahashi2, Hiroyasu Aoki3, Masaki Kurosu1, Haru Ogiwara1, Shigeyuki Shichino1, Kouji Matsushima1, Satoshi Ueha1 (1.Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, 2.Faculty of Medicine, The University of Tokyo, 3.Department of Preventive Medicine, Graduate School of Medicine, The University of Tokyo.)
[WS29-10-P]Combination of T cell therapy and a compound 433 overcomes tumor heterogeneity
○Pengyu Miao1, Situo Deng1, Daisuke Ehara1,2, Daisuke Muraoka3, Naohisa Ogo4, Mitsuhiro Yoneda1, Kiyoshi Yasui1, Akira Asai4, Hiroaki Ikeda1 (1.Dept. of Oncology, Nagasaki Univ. Grad. Sch. of Biomed. Sci, 2.Dept. of Dermatology, Nagasaki Univ. Grad. Sch. of Biomed. Sci, 3.Div. of Translational Oncoimmunology, Aichi Cancer Ctr. Res. Inst, 4.Ctr. for Drug Discovery, Grad. Div Pharm., Univ. of Shizuoka)
[WS29-11-O/P]Withdrawn
[WS29-12-P]Antibody-dependent cellular cytotoxicity of induced pluripotent stem cell-derived natural killer T cells by anti-GD2 monoclonal antibody for neuroblastoma
○Katsuhiro Nishimura1,2, Takahiro Aoki1,3, Midori Kobayashi1, Mariko Takami1, Daisuke Katsumi1,2, Hiroko Yoshizawa1,2, Shugo Komatsu2, Haruhiko Koseki4, Tomoro Hishiki2, Shinichiro Motohashi1 (1.Department of Medical Immunology, Graduate School of Medicine, Chiba University, 2.Department of Pediatric Surgery, Graduate School of Medicine, Chiba University, 3.Department of Pediatrics, Graduate School of Medicine, Chiba University, 4.Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences)
[WS29-13-P]Establishment and induction of long-term cancer immune memory by RK-LIPO activated NKT cells and elucidation of its antitumor mechanism
○Toshi Jinnohara1, Masumi Takahashi1, Takashi Taida2, Masaru Taniguchi1, Hiroshi Ohno1 (1.RIKEN IMS, 2.Chiba Univ)
[WS29-14-P]Engineering TCR-controlled Fuzzy Logic into CAR T Cells Enhances Therapeutic Specificity
○Taisuke Kondo1, François Bourassa2, Sooraj Achar1,3, Grégoire Altan-Bonnet1, Paul François2, Naomi Taylor1 (1.National Institutes of Health, 2.McGill University, 3.University of Oxford)
[WS29-15-P]A combination of systemic plus intra-tumor neopeptide vaccination controls tumors in a mouse model
○Kou Hioki1, Melisa D. Castro Eiro1, Ling Li1, Marlous Wildemans1, Youkyung Lim1, Harmen J. G. van de Werken1, Yvonne M. Mueller1, Burcu Temizoz2, Kouji Kobiyama2, Christopher Schliehe1, Ken J. Ishii2, Peter D. Katsikis1 (1.Department of Immunology; Erasmus University Medical Center, Rotterdam, the Netherlands, 2.Division of Vaccine Science, Department of Microbiology and Immunology, International Vaccine Design Center (vDesC), The Institute of Medical Science, The University of Tokyo (IMSUT), Tokyo, Japan)
[WS29-16-P]Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes
○Serina Tokita1,2, Takayuki Kanaseki1,2, Toshihiko Torigoe1,2 (1.Department of Pathology, Sapporo Medical University, 2.Joint Research Center for Immunoproteogenomics, Sapporo Medical University)
[WS29-17-P]HLA-II neoantigen presentation in the TME and CD4+ T cell surveillance in colorectal cancer
○Satoru Matsumoto1,2, Takayuki Kanaseki1,3, Takahiro Tsujikawa4, Serina Tokita1,3, Toshihiko Torigoe1 (1.Department of Pathology, Sapporo Medical University School of Medicine, 2.IMS Sapporo Digestive Disease Center General Hospital, 3.Sapporo Medical University Joint Research Center for Immunoproteogenomics, 4.The Department of Otorhinolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine)
[WS29-18-P]Development of mRNA vaccines targeting common cancer antigens
○Nobuo Tsukamoto, Honoka Nishide, Hiroki Kinoshita, Kazunobu Onuki, Alicia Cristina Pena-Romero, Kazumasa Takenouchi, Tetsuya Nakatsura (Division of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center)
[WS29-19-P]IFN-γ-Induced MHC Class II Expression on Tumor Cells Plays a Crucial Role in Anti-Cancer Immunity Induced by mRNA Cancer Vaccine
○Mahiro Shibata1,2, Hui Jin1,2, Hisashi Arase1,2 (1.Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, 2.Laboratory of Immunochemistry, Frontier Research Center for Immunology, Osaka University)
[WS29-20-P]Bacterial infection Induces transient melanoma dedifferentiation with attenuated antigenicity
○Yutaka Horiuchi, Sara Hatazawa, Yukie Ando, Momo Mataki, Takashi Murakami (Dept. Microbiol., Fac. Med., Saitama Med. Univ.)
[WS29-21-P]Peptide immunotherapy targeting FAP-positive fibroblasts
○Keiko Udaka1, Taro Komatsu1, Yuki Tanaka2, Kousuke Onoue2, Yoshiko Yamashita2, Kazuhide Onoguchi2, Ryo Tanaka3, Yoichiro Iwase3, Naoki Sakaguchi3,4 (1.Department of Immunology, School of Medicine, Kochi University, 2.Division of AI Drug Development, NEC Corporation, 3.Pharmaceutical Solutions Division, R&D, TERUMO Corporation, 4.previous affiliation)
[WS29-22-P]MONTANIDTM ISA 51 VG: open access adjuvant dedicated to therapeutic vaccines
○Ko Sugahara1, Jaymes Bryant Tibig2,3, Dorine Hello2 (1.Air Liquide Japan GK, 2.SEPPIC SA, 3.Université Claude Bernard Lyon)
[WS29-23-P]Intradermal injection of protein using a needle-free pyro-drive jet injector augments potent CD8+ T cell-mediated antitumor immunity via its shear stress-induced HMGB1
○Izuru Mizoguchi1, Jukito Sonoda1, Natsuki Yamaguchi1, Eri Horio1, Satomi Miyakawa1, Mingli Xu1, Toshihiko Yoneto1, Yasuhiro Katahira1, Hideaki Hasegawa1, Takashi Hasegawa2, Kunihiko Yamashita2, Takayuki Yoshimoto1 (1.Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 2.Department of Device Application for Molecular Therapeutics, Graduate School of Medicine, Osaka University)
[WS29-24-P]Enhancing whole-cell vaccine effectiveness by inducing immunogenic cell death in combination with needle-free injectors
○Kunihiko Yamashita1,3, Chin-Yang Chang2, Jiayu A. Tai1, Yu-Diao Kuan1, Tomoyuki Nishikawa1 (1.Department of Device Application for Molecular Therapeutics,Graduate School of Medicine/Faculty of Medicine,Osaka Univ., 2.Department of Gene and Stem Cell Regenerative Therapy, Graduate School of Medicine/Faculty of Medicine,Osaka Univ., 3.Daicel Corporation)
[WS29-25-P]Analyzing the Effectiveness of Recombinant Oncolytic Vaccinia Viruses with Human b-Defensin 2 in Boosting Anti-Tumor Immunity using Predictive Modelling of Immune Responses
○Prihantini Prihantini1, Rifaldy Fajar2, Sahnaz Vivinda Putri3, Andi Nursanti Ureng4 (1.Bandung Institute of Technology, 2.Yogyakarta State University, 3.Daeng Radja Hospital, 4.Andini Persada College of Health Sciences)
[WS29-26-O/P]In vivo Generation of Designer antigen-presenting cells using mRNA for Cancer Immunotherapy
○Tomoyoshi Yamano, Toan Van Le, Shota Imai, Iriya Fujitsuka, RIkinari Hanayama (Department of Immunology, Kanazawa University)
[WS29-27-P]A novel cell therapy using CCL19-expressing allogeneic mesenchymal stem cells exerts robust anti-tumor effects by accumulating CD103+ dendritic cells and priming CD8+ T cells without involving draining lymph nodes
○Yuichi Iida, Mamoru Harada (Department of Immunology, Faculty of Medicine, Shimane University)
[WS29-28-O/P]Antitumor immunity via harnessing nano-sized membrane vesicles
○Mirei Kataoka1, Yusuke Ito1, Seiichi Ohta2, Yuki Kagoya1 (1.Keio University, 2.The University of Tokyo)
[WS29-29-P]Development and evaluation of a novel DDS formulation using shark antibodies
○Yuki Nitta1,2, Wataru Takagi1, Susumu Hyodo1, Masahiro Yasunaga1,2 (1.Tokyo Univ., 2.National Cancer Center)